(Image source: xconomy.com) Shares of the biopharmaceutical company Halozyme Therapeutics, Inc. (NASDAQ:HALO) are rallying in early trading as a result of a clinical trial for cellulite meeting the company’s expectations. The experimental cellulite drug (HTI-501) during phase I testing showed signs of decreasing cellulite on patients. Millions of women suffer from cellulite.